How Direct-to-Patient trial design benefits sponsors and patients
Direct-to-Patient models allow for study medications to be administered in a patient’s home rather than a trial site. Read our white paper to learn how this is helping sponsors improve patient enrollment and retention.
Download the white paper to see how we provide an in-depth analysis of the importance of optimizing your RTSM system for your organization by focusing on reducing significant financial losses and decrease delays
and implementing best practices.
Machine learning has been a buzz phrase in biopharma for some time now, even though some in the industry still struggle to define it. Many wonder whether the reality of artificial intelligence can live up to its hype and if it does have a serious role to play, whether regulators are ready to embrace its use.
The US Food and Drug Administration (FDA) recently published a guidance for industry on the use of electronic health record (EHR) data in FDA-regulated clinical investigations, with the goal of modernizing studies by using EHR data and including real-world data.
Advance your career among a passionate and diverse group of scientists, technologists, and designers, as we continue to transform clinical research in the hope for life-saving treatments. Join our collaborative, fast paced team where employees are given autonomy and encouraged to take risks. Are you ready for the challenge?